- Home
- PAYO vs VERA Comparison
PAYO vs VERA Comparison
Compare PAYO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- VERA
- Stock Information
- Founded
- PAYO 2005
- VERA 2016
- Country
- PAYO United States
- VERA United States
- Employees
- PAYO N/A
- VERA N/A
- Industry
- PAYO EDP Services
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- VERA Health Care
- Exchange
- PAYO Nasdaq
- VERA Nasdaq
- Market Cap
- PAYO 3.2B
- VERA 2.5B
- IPO Year
- PAYO N/A
- VERA 2021
- Fundamental
- Price
- PAYO $8.66
- VERA $42.01
- Analyst Decision
- PAYO Strong Buy
- VERA Strong Buy
- Analyst Count
- PAYO 7
- VERA 9
- Target Price
- PAYO $8.93
- VERA $53.56
- AVG Volume (30 Days)
- PAYO 2.0M
- VERA 683.6K
- Earning Date
- PAYO 11-05-2024
- VERA 11-07-2024
- Dividend Yield
- PAYO N/A
- VERA N/A
- EPS Growth
- PAYO 447.53
- VERA N/A
- EPS
- PAYO 0.26
- VERA N/A
- Revenue
- PAYO $900,058,000.00
- VERA N/A
- Revenue This Year
- PAYO $14.06
- VERA N/A
- Revenue Next Year
- PAYO $7.49
- VERA N/A
- P/E Ratio
- PAYO $32.93
- VERA N/A
- Revenue Growth
- PAYO 21.43
- VERA N/A
- 52 Week Low
- PAYO $4.22
- VERA $9.68
- 52 Week High
- PAYO $8.60
- VERA $50.78
- Technical
- Relative Strength Index (RSI)
- PAYO 81.47
- VERA 52.57
- Support Level
- PAYO $8.27
- VERA $39.22
- Resistance Level
- PAYO $8.56
- VERA $50.00
- Average True Range (ATR)
- PAYO 0.16
- VERA 2.41
- MACD
- PAYO 0.02
- VERA 0.24
- Stochastic Oscillator
- PAYO 100.00
- VERA 28.53
About PAYO Payoneer Global Inc.
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started to empower global commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.